

**International Conference**  
**“CLINICAL GENETICS OF CANCER 2016”**

**Szczecin, 14-15 September 2016**

**(Center for New Medical Technologies, Unii Lubelskiej 1, Szczecin)**

**Wednesday (14 September 2016)**

<b>9:00-9:15</b>	<b>Conference opening</b>
9:15-9:45	DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients. (R. Scott, Australia)
9:45-10:00	Methylation of BRCA1 promoter in women with breast cancer in Polish Population. (K. Prajzencanc, Poland)
10:00-10:20	The Power of Founder Populations in Gene Discovery. (M. Akbari, Canada)
<b>10:20-11:10</b>	<b>Coffee break</b>
11:10-11:30	New genes associated with a high risk of breast cancer. (C. Cybulski, Poland)
11:30-11:45	The APOBEC3B deletion - determination of its consequences on mRNA level and analysis of its role in familial breast cancer predisposition. (K. Klonowska, Poland)
11:45-12:05	Comprehensive of BRCA1/2-associated breast cancer evidence in Lithuania: 10 years' experience. (P. Elsakov, Lithuania)
12:05-12:25	BRCA1-associated ovarian cancer in Belarus: towards a more complete picture. (A. Savanevich, Belarus)
12:25-12:45	Genetic counseling. Our experience of creating Hereditary cancer center. (A. Ilin, Russia)
12:45-13:05	A population screening - detection of BRCA1 and other genes founder mutations. (J. Gronwald, Poland)
<b>13:05-14:40</b>	<b>Lunch</b>

- 14:40-15:00 Old and new drugs for hereditary cancers. (E. N. Imyanitev, Russia)
- 15:00-15:20 Extent of Axillary surgery in BRCA1 positive breast cancer cases. (A. Irmejs, Latvia)
- 15:20-15:35 The type of recurrence in patients diagnosed with breast cancer and founder mutations in *CHEK2* gene – experience of one center. (M. Szwiec, Poland)
- 15:35-15:50 Oophorectomy in the treatment of breast cancer in carriers of *CHEK2* mutation. (M. Szwiec, Poland)
- 15:50-16:10 Selenium as prognostic marker for cancer patients. (J. Lubiński, Poland)
- 16:10-16:55 Coffee break**
- 16:55-17:10 Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer? (M. Lener, Poland)
- 17:10-17:25 Zastosowanie metody elektroporacji w badaniach przełamaniu oporności wielolekowej komórek białaczkowych człowieka na przykładzie genu MDR1. (J. Kocki, Poland)
- 17:25-17:45 Zwiększenie efektywności diagnostyki wczesnych stanów onkologicznych poprzez wykorzystanie różnych programów przesiewowo-diagnostycznych. (A. Prusaczyk, Poland)
- 17:45-18:45 Zebranie Sekcji Genetyki Klinicznej Nowotworów, Polskiego Towarzystwa Genetyki Człowieka.
- 18:45 Dinner**

## Thursday (15 September 2016)

- 8:30-9:00            Epidemiology and genetics of familial cancer. (K. Hemminki, Germany)
- 9:00-9:30            Hereditary Leukemia and Myelodysplastic syndromes. (R. Sijmons, Netherlands)
- 9:30-9:55            Spectrum of APC mutations in Poland. (A. Pławski, Poland)
- 9:55-10:15          Contribution of MLH1, MSH2 and MSH6 germline mutations to Pakistani Colorectal Cancer patients. (M. U. Rashid, Pakistan)
- 10:15-10:30          New *EPCAM* founder mutation in Polish population. (D. Dymerska, Poland)
- 10:30-10:50          Effectiveness of detection of mutations within genes predisposing to Lynch Syndrome. (T. Dębniak, Poland)
- 10:50-11:20          Coffee break**
- 11:20-11:35          The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients. (T. Huzarski, Poland)
- 11:35-11:45          Vitamin D concentration and variants of VDR gene as a markers of detection of breast, lung, prostate and colorectal cancers. (T. Gromowski, Poland)
- 11:45-11:55          Serum Zinc level as a risk marker for cancers. (K. Kaczmarek, Poland)
- 11:55-12:05          Serum Copper level as a risk marker for cancers. (M. Muszyńska, Poland)
- 12:05-12:15          Cadmium, mercury, lead and selenium as a risk markers for cancers. (W. Marciniak, Poland)
- 12:15-12:35          Progress in realization of INNOMED project. (J. Lubiński, Poland)
- 12:35-12:55          Zwiększenie efektywności pracy poprzez narzędzia elektroniczne. (A. Prusaczyk, Poland)
- 12:55                  **Closing**  
**Lunch**

**Honorary patronage / Honorowy patronat:**

**Marshal of the Zachodniopomorskie Voivodeship /  
Marszałek Województwa Zachodniopomorskiego, Olgierd  
Geblewicz**



PATRONAT HONOROWY  
MARSZAŁKA WOJEWÓDZTWA  
ZACHODNIOPOMORSKIEGO  
OLGIERDA GEBLEWICZA

**Rector of Pomeranian Medical University /  
J.M. Rektor PUM, prof. dr hab. n. med. Bogusław Machaliński**



**Pomorski Uniwersytet Medyczny  
w Szczecinie**

**Okręgowa Izba Lekarska w Szczecinie**




## Sponsors / Sponsorzy:



Marszałek Województwa  
Zachodniopomorskiego



Pomorski Uniwersytet Medyczny  
w Szczecinie




# Lab Empire

## Organisers / organizatorzy:

Zakład Genetyki i Patomorfologii PUM w Szczecinie

International Hereditary Cancer Center of Pomeranian Medical University in  
Szczecin /

Międzynarodowe Centrum Nowotworów Dziedzicznych Pomorskiego Uniwersytetu  
Medycznego w Szczecinie



Section of Cancer Clinical Genetics of Polish Society of Human Genetics /  
Sekcja Genetyki Klinicznej Nowotworów Polskiego Towarzystwa Genetyki Człowieka